Clinical trial
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or…
NCT00290706 · Northwestern University, Other · Terminated
Key facts
| NCT number | NCT00290706 |
|---|---|
| Title | A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma |
| Official title | A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Eli Lilly and Company Industry Millennium Pharmaceuticals, Inc. |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib, gemcitabine hydrochloride |
| Enrollment | 32 |
| Start date | Apr 7, 2006 |
| Primary completion | Feb 11, 2011 |
| Completion | Sep 5, 2012 |
| First posted | Feb 13, 2006 |
| Last update posted | May 28, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: